Walgreens, a major national pharmacy chain, has reached a settlement with the U.S. government for a hefty $300 million over allegations related to the illegal filling of opioid prescriptions and making false claims to federal health care programs, as reported by the Department of Justice. In the alleged wrongdoing, which spanned from August 2012 to March 2023, Walgreens is said to have filled millions of prescriptions that lacked legitimate medical purposes.
"Pharmacies have a legal responsibility to prescribe controlled substances in a safe and professional manner, not dispense dangerous drugs just for profit," Attorney General Pamela Bondi stated, emphasizing the gravity of the responsibilities laid at the feet of pharmacies nationwide. According to a CBS12 report, the settlement also included a provision that could see Walgreens pay an additional $50 million, if the company undergoes a sale, merger, or transfer before fiscal year 2032.
Beyond the financial repercussions, Walgreens also entered into agreements with the Drug Enforcement Administration (DEA) and Department of Health and Human Services Office of Inspector General (HHS-OIG) to bolster its dispensing practices. These agreements demand a more rigorous adherence to compliance measures, including the validation of controlled substance prescriptions and annual training for pharmacy employees.
Amidst widespread outcry over the opioid crisis and the role of pharmacies in exacerbating it, DEA Acting Administrator Derek Maltz remarked, "When one of the nation's largest pharmacies fails at this obligation, they jeopardize the health and safety of their customers and place the American public in danger." This sentiment is reflective of a broader, ongoing concern about the role of pharmaceutical entities in the improper distribution of highly addictive medications, as per the Department of Justice's release. Furthermore, the aforementioned settlement resolves four cases brought under whistleblower provisions of the False Claims Act (FCA) which alleges that Walgreens failed in their duty to responsibly control the dispensation of opioids.
The resolution of this case is no small victory for the government, which has been steadfast in its commitment to tackle healthcare fraud and hold accountable the entities contributing to the opioid epidemic. The Department of Justice, through these and similar actions, is signaling a clear intent to relentlessly pursue and rectify the transgressions that have undermined the nation's healthcare systems and patient safety.
